Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells <i>in vitro</i>

Kouhpaykar, Hamideh and Sadeghian, Mohammad Hadi and Rafatpanah, Houshang and Kazemi, Mohadeseh and Iranshahi, Mehrdad and Delbari, Zahra and Khodadadi, Faezeh and Ayatolahi, Hossein and Rassouli, Fatemeh B. (2020) Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells <i>in vitro</i>. Iranian Journal of Basic Medical Sciences, 23 (5). pp. 616-622.

Full text not available from this repository.
Official URL: http://ijbms.mums.ac.ir/article_14630.html

Abstract

Objective(s): Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoid malignancy with low survival rate and distinct geographical distribution. In search for novel chemotherapeutics against ATLL, we investigated the combinatorial effects of parthenolide, a sesquiterpene lactone with valuable pharmaceutical activities, and arsenic trioxide (ATO) in vitro. Materials and Methods: MT2 cells, an ATLL cell line, were treated with increasing concentrations of parthenolide (1.25, 2.5, and 5 μg/ml) and ATO (2, 4, 8, and 16 µM) to determine their IC50. Then, cells were treated with a combination of sub-IC50 concentrations of parthenolide (1 μg/ml) and ATO (2 µM) for 72 hr. Cell viability and cell cycle changes were assessed by Alamar blue and PI staining, respectively. To understand the mechanisms responsible for observed effects, expression of CD44, NF-κB (REL-A), BMI-1, and C-MYC were investigated by real-time PCR.Results: Assessment of cell viability indicated that parthenolide significantly increased the toxicity of ATO, as confirmed by accumulation of MT2 cells in the sub G1 phase of the cell cycle. Moreover, molecular analysis revealed significant down-regulation of CD44, NF-κB (REL-A), BMI-1, and C-MYC upon combinatorial administration of parthenolide and ATO in comparison with relevant controls.Conclusion: Taken together, present results showed that parthenolide significantly enhanced the toxicity of ATO in MT2 cells. Therefore, the future possible clinical impact of our study could be combinatorial use of parthenolide and ATO as a novel and more effective approach for ATLL.

Item Type: Article
Uncontrolled Keywords: Adult T-cell Leukemia/Lymphoma,Arsenic Trioxide,In vitro,Parthenolide,PCR
Subjects: QV pharmacology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 23 Jun 2020 09:56
Last Modified: 23 Jun 2020 09:56
URI: http://eprints.mums.ac.ir/id/eprint/18057

Actions (login required)

View Item View Item